- Home
- SPPL vs CVKD Comparison
SPPL vs CVKD Comparison
Compare SPPL & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPPL | CVKD |
|---|---|---|
| Founded | 2016 | 2022 |
| Country | Singapore | United States |
| Employees | N/A | 4 |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 18.4M |
| IPO Year | 2023 | 2023 |
Fundamental Metrics
Financial Performance| Metric | SPPL | CVKD |
|---|---|---|
| Price | $4.21 | $10.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | 3.5K | ★ 17.4K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,591,508.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.27 | N/A |
| 52 Week Low | $2.18 | $8.12 |
| 52 Week High | $16.80 | $22.90 |
Technical Indicators
Market Signals| Indicator | SPPL | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 47.10 | 46.78 |
| Support Level | $3.49 | $8.12 |
| Resistance Level | $4.75 | $11.29 |
| Average True Range (ATR) | 0.23 | 0.85 |
| MACD | 0.04 | -0.08 |
| Stochastic Oscillator | 57.85 | 59.78 |
Price Performance
Historical ComparisonAbout SPPL SIMPPLE LTD.
Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.